FluoSphera has developed in vitro human biosystems that mimic essential features of human body organization.
FluoSphera's biosystems generate data that predict much better the effects of drugs on patients, thus reducing the costs of drug development failure up to several hundreds of million dollars per drug.
Using this technology, FluoSphera proposes R&D services to pharmaceutical companies willing to de-risk drug development projects.
Drug profiling with our biosystems allows the discovery of more efficient drugs for the patients, with less adverse side effects, and it contributes to reduce animal experimentation.
FluoSphera's biosystems generate data that predict much better the effects of drugs on patients, thus reducing the costs of drug development failure up to several hundreds of million dollars per drug.
Using this technology, FluoSphera proposes R&D services to pharmaceutical companies willing to de-risk drug development projects.
Drug profiling with our biosystems allows the discovery of more efficient drugs for the patients, with less adverse side effects, and it contributes to reduce animal experimentation.
Location: Switzerland, Geneva
Total raised: $2.27M
Investors 3
| Date | Name | Website |
| 09.11.2021 | Venture Ki... | venturekic... |
| - | EFI Lake G... | lakegeneva... |
| 07.07.2023 | Mountain L... | mountainla... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.01.2024 | Grant | $1.27M | - |
| 01.03.2023 | Pre-Seed | $1M | IndieBio |
Mentions in press and media 13
| Date | Title | Description |
| 05.11.2024 | Bio Europe in Stockholm hosts 33 Swiss companies | Currently in its 30-year-edition, BIO-Europe remains Europe's leading partnering event, for the life sciences ecosystem, providing an exceptional opportunity to explore the latest trends learn and connect with potential partners. The past ... |
| 11.06.2024 | FluoSphera and Revvity Collaborate to Develop a Multiplexed Selectivity Assay for In Vitro Drug Discovery | Combining our technology with Revvity’s creates a novel in vitro drug discovery solution with the ability to conduct unbiased comparisons through evaluation of multiple tissue types.” — Clelia Bourgoint, Ph.DGENEVA, SWITZERLAND, June 11, 20... |
| 31.05.2024 | Swiss life science startups headed for San Diego | The BIO International Convention 2024, taking place in San Diego from 3 to 6 June, is the largest global biotechnology event with over 20,000 industry leaders from around the world attending. The target group includes representatives from ... |
| 25.01.2024 | FluoSphera's revolutionary drug discovery project secures CHF 1.1 million grant from Innosuisse | FluoSphera is set to start a two-year research project with a budget of CHF 2.3 million, focusing on overcoming challenges in predicting drug toxicity effects in humans. The FluoSphera platform, unlike traditional translational methods, ass... |
| 05.06.2023 | A significant number of Swiss biotechs exhibit in Boston | |
| 16.05.2023 | FIF supports Fluosphera, Kylys Aesthetics and Consulto | |
| 01.03.2023 | FluoSphera secures $1 million pre-seed investment | |
| 23.05.2022 | Swiss Biotechs display their innovations at BIO 2022 International Convention | |
| 15.02.2022 | CHF 40,000 for multi-tissue systems and textile-integrated tissue oxygenation sensors | Fluosphera: Multi-tissue systems for a reliable prediction of efficacy and toxicity of drugs Drug development costs CHF 2.6 billion with a failure rate of 90% because in vitro methods do not recapitulate the systemic organization of the hum... |
| 09.11.2021 | The AIT India digital edition kicks off |
Show more